🌍 Material News · FEROZ Ferozsons Laboratories Limited has entered into a royalty-free voluntary licensing agreement with Gilead for the investigational once-yearly lenacapavir for HIV prevention, expanding its previous twice-yearly access strategy. This agreement allows Ferozsons to manufacture and sell lenacapavir in 120 high-incidence countries, primarily targeting low- and lower-middle-income regions.
- Ferozsons is one of six global partners to sign this expanded licensing agreement.
- The agreement supports manufacturing readiness, technology transfer, and future supply planning during the ongoing Phase 3 PURPOSE 365 trial.
- Lenacapavir, if approved, could provide a full year of HIV prevention with a single dose, addressing barriers to PrEP uptake.
- The injectable drug will be manufactured at Ferozsons’ JV Subsidiary, BF Biosciences Limited, under a contract manufacturing agreement.
- The company is preparing for the upcoming availability of the generic version, reflecting a commitment to increase access to HIV prevention in regions with high unmet needs.
About this brief: prepared automatically by BSL’s research systems from the company’s filing with the exchange. A summary for information, not investment advice — the original filing is the authoritative record.
Original filing (PDF)